tiprankstipranks
Bio-Rad Laboratories (DE:BUWA)
NYSE:BUWA
Germany Market
BUWA
Bio-Rad Laboratories
RESEARCH TOOLSreports

Bio-Rad Laboratories (BUWA) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

BUWA Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
1 Buy
2 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Bio-Rad
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BUWA Stock 12 Month Forecast

Average Price Target

€264.20
▲(3.85% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Bio-Rad Laboratories in the last 3 months. The average price target is €264.20 with a high forecast of €280.26 and a low forecast of €240.85. The average price target represents a 3.85% change from the last price of €254.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"202":"€202","281":"€281","221.75":"€221.8","241.5":"€241.5","261.25":"€261.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":280.2572768,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€280.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":264.2008703166667,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€264.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":240.84609724999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€240.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[202,221.75,241.5,261.25,281],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,260.4,261.92748283076924,263.45496566153844,264.9824484923077,266.5099313230769,268.03741415384616,269.56489698461536,271.0923798153846,272.6198626461538,274.1473454769231,275.6748283076923,277.20231113846154,278.72979396923074,{"y":280.2572768,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,260.4,260.69237463974355,260.9847492794872,261.27712391923075,261.5694985589744,261.86187319871794,262.1542478384615,262.44662247820514,262.7389971179487,263.0313717576923,263.3237463974359,263.6161210371795,263.9084956769231,{"y":264.2008703166667,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,260.4,258.8958536346154,257.3917072692307,255.88756090384612,254.38341453846152,252.8792681730769,251.3751218076923,249.87097544230767,248.36682907692307,246.86268271153844,245.35853634615384,243.8543899807692,242.3502436153846,{"y":240.84609724999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":203.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":251.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":275.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.8,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":251.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":238.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":239.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":261.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260.4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€280.26Average Price Target€264.20Lowest Price Target€240.85
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:BUWA
Brandon Couillard
Wells Fargo
Wells Fargo
€253.98→€271.5
Hold
6.72%
Upside
Reiterated
05/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (NYSE: BIO) and Haleon PLC Sponsored ADR (NYSE: HLN)
Jefferies Analyst forecast on DE:BUWA
Tycho Peterson
Jefferies
Jefferies
€240.85
Hold
-5.33%
Downside
Reiterated
05/21/26
Jefferies Keeps Their Hold Rating on Bio-Rad Laboratories (BIO)
RBC Capital Analyst forecast on DE:BUWA
Dan Leonard
RBC Capital
RBC Capital
€280.26
Buy
10.16%
Upside
Initiated
05/14/26
Bio-Rad resumed with an Outperform at RBC CapitalBio-Rad resumed with an Outperform at RBC Capital
Citi Analyst forecast on DE:BUWA
Patrick B Donnelly
Citi
Citi
€328.43→€262.74
Hold
3.28%
Upside
Downgraded
04/07/26
Bio-Rad downgraded to Neutral from Buy at CitiBio-Rad downgraded to Neutral from Buy at Citi
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:BUWA
Brandon Couillard
Wells Fargo
Wells Fargo
€253.98→€271.5
Hold
6.72%
Upside
Reiterated
05/22/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (NYSE: BIO) and Haleon PLC Sponsored ADR (NYSE: HLN)
Jefferies Analyst forecast on DE:BUWA
Tycho Peterson
Jefferies
Jefferies
€240.85
Hold
-5.33%
Downside
Reiterated
05/21/26
Jefferies Keeps Their Hold Rating on Bio-Rad Laboratories (BIO)
RBC Capital Analyst forecast on DE:BUWA
Dan Leonard
RBC Capital
RBC Capital
€280.26
Buy
10.16%
Upside
Initiated
05/14/26
Bio-Rad resumed with an Outperform at RBC CapitalBio-Rad resumed with an Outperform at RBC Capital
Citi Analyst forecast on DE:BUWA
Patrick B Donnelly
Citi
Citi
€328.43→€262.74
Hold
3.28%
Upside
Downgraded
04/07/26
Bio-Rad downgraded to Neutral from Buy at CitiBio-Rad downgraded to Neutral from Buy at Citi
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bio-Rad Laboratories

3 Months
Dan LeonardRBC Capital
Success Rate
13/21 ratings generated profit
62%
Average Return
+5.58%
Copying Dan Leonard's trades and holding each position for 3 Months would result in 61.90% of your transactions generating a profit, with an average return of +5.58% per trade.
1 Year
Dan LeonardRBC Capital
Success Rate
10/21 ratings generated profit
48%
Average Return
+4.46%
Copying Dan Leonard's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +4.46% per trade.
2 Years
Dan LeonardRBC Capital
Success Rate
10/21 ratings generated profit
48%
Average Return
-2.70%
Copying Dan Leonard's trades and holding each position for 2 Years would result in 47.62% of your transactions generating a profit, with an average return of -2.70% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BUWA Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
2
2
1
1
1
Hold
1
2
4
4
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
4
5
5
4
In the current month, BUWA has received 1 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. BUWA average Analyst price target in the past 3 months is 264.20.
Each month's total comprises the sum of three months' worth of ratings.

BUWA Financial Forecast

BUWA Earnings Forecast

Next quarter’s earnings estimate for BUWA is €1.53 with a range of €1.35 to €1.80. The previous quarter’s EPS was €1.66. BUWA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BUWA has Performed in-line its overall industry.
Next quarter’s earnings estimate for BUWA is €1.53 with a range of €1.35 to €1.80. The previous quarter’s EPS was €1.66. BUWA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BUWA has Performed in-line its overall industry.

BUWA Sales Forecast

Next quarter’s sales forecast for BUWA is €546.49M with a range of €544.35M to €549.48M. The previous quarter’s sales results were €518.56M. BUWA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BUWA has Performed in-line its overall industry.
Next quarter’s sales forecast for BUWA is €546.49M with a range of €544.35M to €549.48M. The previous quarter’s sales results were €518.56M. BUWA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BUWA has Performed in-line its overall industry.

BUWA Stock Forecast FAQ

What is DE:BUWA’s average 12-month price target, according to analysts?
Based on analyst ratings, Bio-Rad Laboratories’s 12-month average price target is 264.20.
    What is DE:BUWA’s upside potential, based on the analysts’ average price target?
    Bio-Rad Laboratories has 3.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Bio-Rad Laboratories a Buy, Sell or Hold?
          Bio-Rad Laboratories has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Bio-Rad Laboratories’s share price target?
            The average share price target for Bio-Rad Laboratories is 264.20. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €280.26 ,and the lowest forecast is €240.85. The average share price target represents 3.85% Increase from the current price of €254.4.
              What do analysts say about Bio-Rad Laboratories?
              Bio-Rad Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Bio-Rad Laboratories?
                To buy shares of DE:BUWA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.